FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN

Yang Chih Jen; Tsai Ming-Ju; Hung Jen-Yu; Lee Mei-Hsuan; Huang Ming-Shyan; Chong Inn-Wen

首页> 外文期刊>Respirology : >FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN

【24h】

FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN

机译：一线吉非替尼，厄洛替尼和Afatinib在患者中提供了类似的临床疗效，患者患有罕见的台湾罕见的EGFR突变

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Respirology :》 |2018年第2期|共1页
作者
Yang Chih Jen; Tsai Ming-Ju; Hung Jen-Yu; Lee Mei-Hsuan; Huang Ming-Shyan; Chong Inn-Wen;
展开▼
作者单位

Kaohsiung Med Univ Kaohsiung Taiwan;

Kaohsiung Med Univ Kaohsiung Taiwan;

Kaohsiung Med Univ Kaohsiung Taiwan;

Kaohsiung Med Univ Kaohsiung Taiwan;

E Da Canc Hosp Kaohsiung Taiwan;

Kaohsiung Med Univ Kaohsiung Taiwan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN [J] . Yang Chih Jen, Tsai Ming-Ju, Hung Jen-Yu, Respirology : . 2018,第Suppla2期

机译：一线吉非替尼，厄洛替尼和Afatinib在患者中提供了类似的临床疗效，患者患有罕见的台湾罕见的EGFR突变
2. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations [J] . Lin Yen-Ting, Chen Jin-Shing, Liao Wei-Yu, International Journal of Cancer =: Journal International du Cancer . 2019,第11期

机译：临床结果和次生表皮生长因子受体（EGFR）T790M突变在一线吉非替尼，厄洛替尼和阿凡哚治疗的非小细胞肺癌患者的激活EGFR突变
3. COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS [J] . Holleman M. S., Zaim R., Uyl-De Groot C. A. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：携带EGFR突变的非小细胞肺癌患者一线吉非替尼，厄洛替尼和阿法替尼的成本效用分析
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment [O] . Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, 2016

机译：在对吉非替尼一线治疗产生耐药性后接受铂类化疗的易感EGFR突变的IV期肺腺癌患者中培美曲塞具有显着更好的临床疗效

FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN

著录项

相似文献

相关主题

期刊订阅